Quest Diagnostics reported $11.6B of revenue over the trailing twelve months, +9.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $11.6B (to Q2 2026). Net income: $1.06B, trailing twelve months to Q2 2026. Free cash flow: $1.35B, trailing twelve months to Q2 2026. Operating margin: 14%, trailing twelve months to Q2 2026.

DGXQuest Diagnostics

Healthcare

$231.15+28% 1Y

$231.15

$171.9552 weeks$247.58

DGX as reported

Quest Diagnostics reported $11.6B of revenue over the trailing twelve months, +9.9% on the year before. 11 reported series are charted on this page, each one as filed.

$11.6B

Revenue, trailing twelve months · to Q2 2026 · +9.9% against the twelve months before

Net income: $1.06B
Net income · +12% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.35B
Free cash flow · +10% year on year · trailing twelve months to Q2 2026
Operating margin: 14%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DGX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$11.6B	+9.9%	Q2 2026
Net income	$1.06B	+12%	Q2 2026
EPS	$9.42	+13%	Q2 2026
Gross margin	33%	n/a	Q2 2026
Operating margin	14%	n/a	Q2 2026
Net margin	9.2%	n/a	Q2 2026
ROE	14%	n/a	Q2 2026
ROA	6.1%	n/a	Q2 2026
ROIC	10.0%	n/a	Q2 2026
Free cash flow	$1.35B	+10%	Q2 2026
P/E	24.5	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.